Synergistic whole-cell Cancer vaccine combining immunogenic cell death and TLR9 agonist elicits potent prophylactic and therapeutic antitumor immunity
International Immunopharmacology · 2026-02 · 171 · 116152
DOI: 10.1016/j.intimp.2025.116152 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-02. Verfasst von Kexing Zhuo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wuhan Asia General Hospital, College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430056, China; Institute of Infection, Imm…. Hauptthemen laut MEDLINE: Cancer Vaccines, Toll-Like Receptor 9, Carcinoma, Lewis Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Chinese Academy of Sciences State Key Laboratory of Biomacromolecules, Hubei Provincial Department of Education, National Natural Science Foundation of China.
Abstract (Originalsprache)
The development of effective cancer vaccines remains challenged by tumor heterogeneity and insufficient T-cell activation. Whole-cell vaccines, which deliver a broad spectrum of tumor-associated antigens, represent a promising approach, especially when their immunogenicity is enhanced via strategies such as immunogenic cell death (ICD). Here, we developed a novel whole-cell vaccine, termed MDLSD, by combining mitoxantrone (MTX)-induced ICD with the TLR9 agonist SD-101. In murine Lewis lung carcinoma (LLC) models, MDLSD demonstrated superior prophylactic and therapeutic efficacy. Mechanistically, MTX-induced dying tumor cells (MDL) promoted dendritic cell (DC) phagocytosis, while the addition of SD-101 was essential for driving complete DC maturation through potent upregulation of CD80. Consequently, only the combined MDLSD vaccine robustly primed antigen-specific T cells in vivo, eliciting elevated IFN-γ secretion. Prophylactic vaccination with MDLSD conferred 100 % protection against initial tumor challenge and durable immunity upon rechallenge. In a therapeutic setting, MDLSD treatment achieved a 55 % complete regression rate, significantly suppressing established tumor growth and prolonging survival. This potent antitumor immunity was driven by MDLSD-enhanced Th1/Tc1 polarization, evidenced by increased T-bet, IFN-γ, and TNF-α, along with boosted cytolytic function via Granzyme B in both systemic and tumor-infiltrating T cells. Furthermore, mice cured by MDLSD developed long-term immunological memory, characterized by a recall response dominated by IFN-γ+ CD8+ and TNF-α+ T cells, enabling rejection of secondary tumor challenges. Collectively, our findings illustrate that the MDLSD vaccine synergizes the antigenic breadth of ICD with potent TLR9 stimulation to elicit robust DC activation, polyfunctional T-cell responses, and durable immunological memory, offering a compelling strategy for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuhan Asia General Hospital, College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430056, China; Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of O…
- Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan 430065, China.
- Wuhan Asia General Hospital, College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430056, China. Electronic address: lilei1@wagh.com.cn.
- Wuhan Asia General Hospital, College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430056, China; Analytical & Testing Center, Wuhan University of Science and Technology, Wuhan, Hubei 430065, Chi…
Förderung
- Chinese Academy of Sciences State Key Laboratory of Biomacromolecules
- Hubei Provincial Department of Education
- National Natural Science Foundation of China
- Wuhan University of Science and Technology
Zitieren
APA
Zhuo, K., Mou, M., Li, J., Huang, S., Zeng, Z., Li, X., Wang, L., Wei, Y., Qiu, S., Wei, X., Li, L., Cao, Y., & Zhong, M. (2026). Synergistic whole-cell Cancer vaccine combining immunogenic cell death and TLR9 agonist elicits potent prophylactic and therapeutic antitumor immunity. International Immunopharmacology, 171, 116152. https://doi.org/10.1016/j.intimp.2025.116152
Vancouver
Zhuo K, Mou M, Li J, Huang S, Zeng Z, Li X, et al. Synergistic whole-cell Cancer vaccine combining immunogenic cell death and TLR9 agonist elicits potent prophylactic and therapeutic antitumor immunity. International Immunopharmacology. 2026;171:116152. doi:10.1016/j.intimp.2025.116152
BibTeX
@article{Zhuo2026,
author = {Zhuo, Kexing and Mou, Man and Li, Jianlun and Huang, Sijian and Zeng, Zihang and Li, Xu and Wang, Lijuan and Wei, Yingjie and Qiu, Shijia and Wei, Xianghong and Li, Lei and Cao, Yuan and Zhong, Maohua},
title = {Synergistic whole-cell Cancer vaccine combining immunogenic cell death and TLR9 agonist elicits potent prophylactic and therapeutic antitumor immunity},
journal = {International Immunopharmacology},
year = {2026},
volume = {171},
pages = {116152},
doi = {10.1016/j.intimp.2025.116152}
}
EUVIMED